Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Gemfibrozil Tablets USP 600 mg (US RLD - LOPID), and Aripiprazole Orally Disintegrating Tablets USP in strengths of 10 mg, 15 mg, 20 mg, and 30 mg (US RLD - ABILIFY DISCMELT Orally Disintegrating Tablets).
Both the drugs will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. In line with this, the group now has 215 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
